Mersana Therapeutics (NASDAQ:MRSN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Saturday.
According to Zacks, “Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company’s product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. “
MRSN has been the topic of several other reports. HC Wainwright set a $33.00 price target on shares of Mersana Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 2nd. JPMorgan Chase downgraded shares of Mersana Therapeutics from an “overweight” rating to a “neutral” rating and set a $23.00 price target on the stock. in a research report on Monday, March 19th. ValuEngine upgraded shares of Mersana Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, Leerink Swann reiterated an “outperform” rating on shares of Mersana Therapeutics in a research report on Wednesday, March 28th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $24.80.
Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings results on Wednesday, March 28th. The company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). The business had revenue of $3.26 million for the quarter, compared to analyst estimates of $4.22 million. sell-side analysts predict that Mersana Therapeutics will post -2.44 EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in MRSN. Vanguard Group Inc. bought a new stake in shares of Mersana Therapeutics during the 2nd quarter valued at $1,048,000. Bank of New York Mellon Corp bought a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at $231,000. California State Teachers Retirement System bought a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at $142,000. Allianz Asset Management GmbH bought a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at $1,419,000. Finally, Victory Capital Management Inc. raised its position in shares of Mersana Therapeutics by 11.0% during the 4th quarter. Victory Capital Management Inc. now owns 57,930 shares of the company’s stock valued at $952,000 after purchasing an additional 5,730 shares during the period. Hedge funds and other institutional investors own 75.73% of the company’s stock.
About Mersana Therapeutics
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.